Influence of the Design of the Transmucosal Abutment on the Periimplant Bone Level

This is an interventional treatment trial for Peri-implant Marginal Bone Loss focused on measuring periimplant bone loss, abutment design, transmucosal abutment Read More

Inclusion Criteria:

• Absence of systemic and periodontal pathology, over 18 years of age, with a plaque index below 25%.
• Absence of at least one tooth, with natural adjacent teeth, allowing a prosthetic rehabilitation with an osseointegrated implant and a prosthetic unit.
• Adequate bone quality available, allowing placement of MOZO GRAU® implants InHex STD QUATTRO with diameters of 3.75 mm or 4.25 mm and lengths of 8, 10 and 11.5 mm.
• Natural teeth or implants with fixed restoration as antagonists.

Exclusion Criteria:

• Systemic factors:

  • Continuous administration of systemic medication that can interfere with the bone metabolism or medical conditions requiring prolonged use of steroids and / or medications that can interfere with bone metabolism.
  • History of leukocyte dysfunction and deficiency, immunodeficiency syndromes, kidney failure or bone metabolic disorders, such as osteoporosis.
  • Physical disability that may interfere with proper oral hygiene.
  • Use of any investigational medication or device within the previous 30 days to implant surgery in the study.
  • Alcoholism or drug addiction
  • Smoker of more than 10 cigarettes per day.
  • Conditions or circumstances that could prevent compliance with participation in study or interfere with the analysis of results, such as a history of breach or unreliability.

Local factors:

• History of local radiotherapy.
• Bruxism.
• Diseases that affect the oral mucosa, such as oral lichen planus.
• Untreated periodontitis.
• Persistent intraoral infection.
• Post-extraction alveoli not cured (less than 6 weeks after extraction).